Hsbc Holdings PLC Acquires 33,077 Shares of Illumina, Inc. $ILMN

Hsbc Holdings PLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 29.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 145,695 shares of the life sciences company's stock after buying an additional 33,077 shares during the period. Hsbc Holdings PLC owned 0.10% of Illumina worth $25,660,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Illumina by 190.1% in the second quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company's stock worth $318,767,000 after buying an additional 1,188,004 shares in the last quarter. Archer Investment Corp purchased a new position in shares of Illumina during the 2nd quarter worth approximately $294,000. Beacon Pointe Advisors LLC bought a new position in shares of Illumina in the 2nd quarter worth approximately $234,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Illumina in the 2nd quarter worth approximately $184,000. Finally, North Star Asset Management Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at approximately $33,039,000. Institutional investors own 89.42% of the company's stock.

Insider Activity at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,062,465 shares of company stock valued at $436,589,802 in the last three months. 2.90% of the stock is owned by insiders.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: S&P 500 inclusion should support demand. Illumina will join the S&P 500 before the market opens on September 21, moving up from the S&P MidCap 400. The change is expected to generate buying from index-tracking funds and increase the company’s visibility among institutional investors. Illumina and Everpure to Join S&P 500 in September Rebalancing
• Positive Sentiment: Analyst sentiment has improved. Zacks upgraded Illumina to Rank #2, or “Buy,” citing greater optimism about its earnings outlook. The upgrade could provide additional short-term momentum. Illumina Upgraded to Buy
• Positive Sentiment: Business quality remains a bullish theme. Commentary highlights Illumina’s leadership in gene sequencing and the expanding use of genomics in diagnostics and precision medicine. Investors are weighing whether continued operational strength can justify the stock’s recent advance. ILMN Stock Keeps Climbing

Illumina Price Performance

ILMN opened at $211.06 on Wednesday. The firm has a market cap of $31.87 billion, a PE ratio of 39.38, a P/E/G ratio of 3.09 and a beta of 1.46. The stock has a 50-day moving average price of $199.86 and a 200-day moving average price of $160.68. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina's revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ILMN. Daiwa Securities Group raised Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price target on the stock in a research note on Thursday, May 14th. JPMorgan Chase & Co. raised their price objective on Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Leerink Partners upped their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. Citigroup lifted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research report on Monday, August 3rd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Illumina in a research note on Monday, August 31st. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $191.31.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.